FDA Clears CoolSculpting for Treatment of ‘Double Chin’


The U.S. Food and Drug Administration has cleared CoolSculpting as the first and only non-surgical fat reduction technology for use to improve the appearance of lax tissue and submental fat treatments, or "double chin," according to Allergan.

“Allergan is committed to advancing innovation for CoolSculpting to meet the needs of patients seeking non-invasive aesthetic treatments,” said David Nicholson, chief research and development officer at Allergan. “A 2017 American Society for Dermatologic Surgery (ASDS) survey revealed that 73% of patients are bothered by excess fat under the chin.2 We are pleased this patient concern can successfully be addressed by CoolSculpting through a non-invasive approach, and furthermore improve the appearance of lax tissue in the treated area.”

CoolSculpting for use on submental fat is clinically proven to reduce fat by up to 20% after one treatment, according to Allergan.1 Additionally, an 18-week study found that 77% of patients showed improvement in the appearance of lax tissue, and 75% of patients reported that their chin appeared more toned after treatment.3


1. Data On File Allergan, Inc.; Safety and Efficacy of Cryolipolysis for Non-Invasive Reduction of Submental Fat, 2016

2. ASDS Consumer Survey, 2017

3. Data on File Allergan, Inc.; Study to Evaluate Non-Invasive Subcutaneous Fat Reduction in the Submental Area Using Cryolipolysis, 2015

More in MedSpa